TissGeneSummary for BTNL9 |
Gene summary |
Basic gene information | Gene symbol | BTNL9 |
Gene name | butyrophilin-like 9 | |
Synonyms | BTN3|BTN8|VDLS1900 | |
Cytomap | UCSC genome browser: 5q35.3 | |
Type of gene | protein-coding | |
RefGenes | NM_152547.4, | |
Description | butyrophilin 3butyrophilin-like protein 9 | |
Modification date | 20141207 | |
dbXrefs | HGNC : HGNC | |
Ensembl : ENSG00000165810 | ||
HPRD : 12550 | ||
Vega : OTTHUMG00000133152 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_BTNL9 | |
BioGPS: 153579 | ||
Pathway | NCI Pathway Interaction Database: BTNL9 | |
KEGG: BTNL9 | ||
REACTOME: BTNL9 | ||
Pathway Commons: BTNL9 | ||
Context | iHOP: BTNL9 | |
ligand binding site mutation search in PubMed: BTNL9 | ||
UCL Cancer Institute: BTNL9 | ||
Assigned class in TissGDB* | C | |
Included tissue-specific gene expression resources | TiGER,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | BreastSoft tissue | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | BRCASARC | |
Reference showing the relevant tissue of BTNL9 | ||
Description by TissGene annotations |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID |
Top |
TissGeneExp for BTNL9 |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
KIRP | -1.483187612 | 0.869771763 | -2.352959375 | 8.33E-11 | 9.73E-10 |
BRCA | -0.698931362 | 3.617166884 | -4.316098246 | 2.45E-60 | 7.89E-58 |
LUAD | -1.341129638 | 3.068268638 | -4.409398276 | 3.45E-33 | 6.45E-31 |
KIRC | 2.407833916 | 0.921770027 | 1.486063889 | 6.19E-12 | 2.46E-11 |
LUSC | -1.781456852 | 3.211194129 | -4.99265098 | 6.10E-23 | 1.03E-21 |
HNSC | -2.332475548 | -1.205633687 | -1.12684186 | 0.00356 | 0.010139241 |
BLCA | -1.839989256 | 0.499610744 | -2.3396 | 8.04E-05 | 0.000926475 |
Top |
TissGene-miRNA for BTNL9 |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for BTNL9 |
TissGeneSNV for BTNL9 |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.H384Y | ACC | 4 |
p.A314S | KIRC | 1 |
p.F75S | SKCM | 1 |
p.A219G | HNSC | 1 |
p.L173F | STAD | 1 |
p.E166K | SKCM | 1 |
p.W146* | SKCM | 1 |
p.R392L | ACC | 1 |
p.R76W | SKCM | 1 |
p.S122N | LGG | 1 |
p.G114V | COAD | 1 |
p.W186R | STAD | 1 |
p.E56G | COAD | 1 |
p.R313W | UCEC | 1 |
p.R443H | BRCA | 1 |
p.R313L | LUSC | 1 |
p.G168D | HNSC | 1 |
p.G132V | UCEC | 1 |
p.G458R | HNSC | 1 |
p.N81S | SKCM | 1 |
p.A261P | CHOL | 1 |
p.N231K | LUAD | 1 |
p.H121Y | BLCA | 1 |
p.A481S | PRAD | 1 |
p.A314G | KIRC | 1 |
p.E199* | ACC | 1 |
p.W146* | LUSC | 1 |
p.L232F | HNSC | 1 |
p.D467N | BLCA | 1 |
p.A439T | COAD | 1 |
p.K12M | COAD | 1 |
p.A439S | LUSC | 1 |
p.L26P | LIHC | 1 |
p.L106M | LIHC | 1 |
p.F140L | UCEC | 1 |
p.A481T | LIHC | 1 |
p.V55M | LUSC | 1 |
p.A481V | COAD | 1 |
p.A434V | BLCA | 1 |
p.E71K | SKCM | 1 |
p.R447Q | STAD | 1 |
p.S10F | SKCM | 1 |
p.S349R | LUAD | 1 |
p.V202I | UCEC | 1 |
p.V82M | PAAD | 1 |
p.L106F | ESCA | 1 |
p.R187T | BRCA | 1 |
p.C59Y | COAD | 1 |
p.S223R | OV | 1 |
p.F140L | BLCA | 1 |
p.L522I | PAAD | 1 |
p.A457V | OV | 1 |
p.R489M | LUAD | 1 |
Top |
TissGeneCNV for BTNL9 |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for BTNL9 |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
Chimerdb3.0 | ChiTaRs | NA | BF919146 | BTNL9-LSM14B | chr5:180469231 | chr20:60709217 |
Top |
TissGeneNet for BTNL9 |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for BTNL9 |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for BTNL9 |
TissGeneDrug for BTNL9 |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for BTNL9 |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |